Factor V Q506 mutation (Activated protein C resistance) associated with reduced intrapartum blood loss - A possible evolutionary selection mechanism

Thrombosis and Haemostasis

Volumn 79, Issue 1, 1998, Pages 69-73

  Lindqvist, Pelle G ^a,b   Svensson, Peter J ^a   Dahlbäck, Björn ^a   Maršál, Karel ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; HEMOGLOBIN; PROTEIN C;

ACTIVATED PROTEIN C RESISTANCE; ALLELE; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; POPULATION GENETICS; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; BLOOD CLOTTING DISORDER; DELIVERY; EVOLUTION; GENETIC SELECTION; GENETICS; MALE; MIDDLE AGED; MUTATION; PHYSIOLOGY; POSTPARTUM HEMORRHAGE; RETROSPECTIVE STUDY;

BLOOD COAGULATION DISORDERS; DELIVERY, OBSTETRIC; EVOLUTION; FACTOR V; FEMALE; FETAL GROWTH RETARDATION; HUMANS; MALE; MIDDLE AGED; MUTATION; POSTPARTUM HEMORRHAGE; PRE-ECLAMPSIA; PREGNANCY; PROTEIN C; RETROSPECTIVE STUDIES; SELECTION (GENETICS);

EID: 0031594157     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614222     Document Type: Article

References (28)

1. Dahlbäck B, Stenflo J. A natural anticoagulant pathway: proteins c, s, c4b-binding protein and thrombomodulin. In: Haemostasis and thrombosis. Bloom A, Forbes C, Thomas D and Tuddenham E (eds). Churchill Livingstone, London 1994; pp 671-98.
2. Greer I. Haemostasis and thrombosis in pregnancy. In: Haemostasis and Thrombosis. Bloom A, Forbes C, Thomas D and Tuddenham E (eds). Churchill Livingstone, London 1994; pp 987-1015.
3. Sipes SL, Weiner CP. Venous thromboembolic disease in pregnancy. Semin Perinatol 1990;14: 103-18.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-8.
5. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
6. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
7. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 344: 694-5.
8. Emmerich J, Poirier O, Evans A, Marques Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.
9. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
10. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995; 15: 783-5.
11. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
12. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. Journal of internal Medicine 1996; 239: 221-6.
13. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
14. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
15. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta 1991; 12: 301-8.
16. Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, van Geijn HP. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-8.
17. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
18. International classification of diseases, ninth revision (ICD-9). World Health organisation, Geneva 1976.
19. Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996; 85: 843-8.
20. Majerus PW. Human genetics. Bad blood by mutation. Nature 1994; 369: 14-5.
21. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-7.
22. Hajjar KA. Factor V Leiden - an unselfish gene? N Engl J Med 1994; 331: 1585-7.
23. Dobbie BM. An attempt to estimate the true rate of maternal mortality, sixteenth to eighteenth centuries. Med Hist 1982; 26: 79-80.
24. Högberg U. Maternal deaths in Sweden, 1971-1980. Acta Obstet Gynecol Scand 1986; 65: 161-7.
25. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89: 397-402.
26. Groube L. The impact of diseases upon the emergence of agriculture. In: The origins and spread of agriculture and pastoralism in Eurasia. Harris D, editor. UCL press, London 1996; pp 101-129.
27. Wiesenfeld SL. Sickle-cell trait in human biological and cultural evolution. Development of agriculture causing increased malaria is bound to gene-pool changes causing malaria reduction. Science 1967; 157: 1134-40.
28. Allison A, Phil D. Protection afforded by sickle-cell trait against subtertian malarial infection. BMJ 1954; 1: 290-4.